Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Transcriptome Subtraction Pinpoints Unknown Viruses in Human Serum

By BiotechDaily International staff writers
Posted on 02 Jul 2013
An approach based on subtracting viral DNA and RNA from that normally present in human serum and then comparing the results to databases of known viral genomes enables screening patients for the presence of unknown viruses.

Investigators at St. Louis University (MO, USA) recently described the use of the next-generation sequencing approach called transcriptome subtraction to look for unknown viral sequences in samples of serum. Transcriptome subtraction requires ultradeep sequencing to establish which DNA and RNA belong to the human genome and separate this material from extraneous viral nucleic acids.

Depth in DNA sequencing refers to the number of times a nucleotide is read during the sequencing process. Deep sequencing indicates that the coverage, or depth, of the process is many times larger than the length of the sequence under study. The term "deep" has been used for a wide range of depths (at least seven times), and the newer term "ultradeep" has appeared in the scientific literature to refer to even higher coverage (at least 100 times). Even though the sequencing accuracy for each individual nucleotide is very high, the very large number of nucleotides in the genome means that if an individual genome is only sequenced once, there will be a significant number of sequencing errors. Furthermore, rare single-nucleotide polymorphisms (SNPs) are common. Hence to distinguish between sequencing errors and true SNPs, it is necessary to increase the sequencing accuracy even further by sequencing individual genomes a large number of times.

After the human genome was identified and removed from the equation, the investigators used data from well-curated databases and advanced bioinformatic tools to eliminate DNA and RNA from all known viruses. Any nucleic acids remaining belonged to unknown viruses.

“We have discovered a technology that allows us to detect new viruses,” said contributing author Dr. Adrian Di Bisceglie, professor of internal medicine at Saint Louis University. “We isolate DNA and RNA, amplify the amount of genetic material present in the blood, do ultradeep sequencing, and use an algorithm to search for matches for every known piece of genetic code, both human and for microbes. Just as the human microbiome project is chronicling the bacteria that live and coexist in every person, we also are studying the human virome to know more about the viruses that live in all of us—we believe not all are harmful and some may even be beneficial.”

The study was published in the June 11, 2013, online edition of the journal Biochemical and Biophysical Research Communications.

Related Links:

St. Louis University



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.